Well Health's Wellstar closes $62-million financing

Executive Summary

• Well Health Technologies Corp.'s majority-owned subsidiary, Wellstar Technologies Corp., has closed a $62 million Series B preferred share financing to support its pre-spinout growth strategy and target a public listing in 2026.
• The financing was led by prominent Canadian investors Mawer Investment Management, Edgepoint Wealth Management, and Picton Investments, building upon a $50.4 million Series A investment raised in December 2024.
• Proceeds will be used for future acquisitions, AI innovation, organic growth, and general corporate purposes, with no shares issued by the parent company, Well Health Technologies.

Key Details

• Transaction Structure: Series B preferred share financing.
• Gross Proceeds: Approximately $62 million.
• Share Issuance: 41,352,598 Series B preferred shares issued.
• Offering Price: $1.50 per Series B share.
• Investors: Mawer Investment Management Ltd., Edgepoint Wealth Management Inc., and Picton Investments.
• Previous Financing Context: Builds on a Series A investment in December 2024, which raised $50.4 million via Series A preferred shares at $1.00 per share.
• Conversion Terms: Series B shares automatically convert into subordinate voting shares of Wellstar upon a qualifying initial public offering (IPO), reverse takeover, or alternative liquidity transaction.
• Dividend Terms: No dividends entitled until 2026; thereafter, quarterly dividends accrue at an increasing rate over time as notional preferred shares until a liquidity event, redemption, or other liquidation event.
• Redemption Rights: Holders may redeem shares at their option after December 31, 2026.
• Use of Proceeds: Future acquisitions, AI-related innovation, organic growth initiatives, and general corporate purposes.
• Advisors: Cormark Securities, Beacon Securities, and Stifel Nicolaus Canada acted as co-lead agents, with Cormark Securities serving as the sole bookrunner.
• Parent Company Impact: Well Health Technologies Corp. did not issue any shares in this transaction; all equity issuances relate solely to Wellstar Technologies.

Notable Quotes

• No direct quotes from executives were included in the provided text.